Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5298777 | 1.00 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL3274604 | 1.00 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL14993243 | 0.89 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL5439110 | 0.84 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL5746176 | 0.84 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL29692705 | 0.84 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL14993065 | 0.81 | MTNR1A (0.37) | KCNH2 | |
| SCHEMBL5744533 | 0.81 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL5441610 | 0.78 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL3611772 | 0.77 | KCNH2 (0.45) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029368-B2 | 3,7-disubstituted octahydro-2H-pyrido[4,3-E][1,3]oxazin-2-one antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-05-12 | — | — | US | disclosed |
| US-20140309218-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-16 | — | — | US | disclosed |
| EP-2785721-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013080156-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | KCNH2 3440/4885 |
| US-20070161627-A1 | Antibacterial agents | NQO2, NQO1, NDUFV2 | KCNH2 2586/4885 |
| US-20140309218-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | OXA1L, TOP1, OGFOD1 | KCNH2 25/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | KCNH2 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.